Emma Walmsley Sells 120,653 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 120,653 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.09), for a total transaction of £1,753,088.09 ($2,182,901.37).

GSK Stock Performance

GSK stock opened at GBX 1,436.50 ($17.89) on Wednesday. GSK plc has a fifty-two week low of GBX 1,282.50 ($15.97) and a fifty-two week high of GBX 1,823.50 ($22.71). The stock’s 50 day simple moving average is GBX 1,361.34 and its two-hundred day simple moving average is GBX 1,455.93. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. The stock has a market cap of £58.61 billion, a price-to-earnings ratio of 1,271.24, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last released its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a return on equity of 33.30% and a net margin of 12.83%. As a group, analysts expect that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on GSK. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank reduced their target price on GSK from GBX 1,820 ($22.66) to GBX 1,600 ($19.92) and set a “buy” rating on the stock in a research note on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.49).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.